Related content

Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma

By Homma Yuki   Taniguchi Koichi   Murakami Takashi   Nakagawa Kazuya   Nakazawa Masatoshi   Matsuyama Ryusei   Mori Ryutaro   Takeda Kazuhisa   Ueda Michio   Ichikawa Yasushi   Tanaka Kuniya   Endo Itaru  

Annals of Surgical Oncology, Vol. 21, Iss. 2, 2014-02 ,pp. : 670-676

Springer Publishing Company

Access to resources Recommend Favorite

Evidence-Based Adjuvant Treatment of Resectable Pancreatic Adenocarcinoma

By Loi Sherene  

American Journal of Cancer, Vol. 4, Iss. 3, 2005-01 ,pp. : 159-168

Adis International

Access to resources Recommend Favorite

Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma

By Tinchon Christoph  

Acta Oncologica, Vol. 52, Iss. 6, 2013-08 ,pp. : 1231-1233

Informa Healthcare

Access to resources Recommend Favorite

Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma

By            

Oncology Letters, Vol. 8, Iss. 3, 2014-01 ,pp. : 1302-1306

Spandidos Publications

Access to resources Recommend Favorite

The impact of liver metastasis on mortality in patients initially diagnosed with locally advanced or resectable pancreatic cancer

By Nakahashi Chigusa   Oda Tatsuya   Kinoshita Taira   Ueda Takanori   Konishi Masaru   Nakagohri Toshio   Inoue Kazuto   Furuse Junji   Ochiai Atsushi   Ohkohchi Nobuhiro  

International Journal of Gastrointestinal Cancer, Vol. 33, Iss. 2-3, 2003-06 ,pp. : 155-164

Humana Press, Inc

Access to resources Recommend Favorite